FENC - Fennec Pharmaceuticals Uzoq muddatli majburiyatlarning kapitalga nisbati

Fennec (FENC) - korporativ logo

Fennec Pharmaceuticals (FENC) qat'iy FDA nazorati va PEDMARK uchun noyob patentlar tufayli yuqori kirish to'siqlaridan foyda ko'rmoqda. Kompaniyaga tegishli daromadlar ximioterapiya oluvchi bolalar uchun eshitishni himoya qiluvchi vositaning sotuviga asoslangan bo'lib, bu GURU.Markets grafigida ko'rsatilgan narxlar dinamikasi bilan tasdiqlanadi, u yerda ko'rsatkich 0.00 darajasida turibdi. Rahbariyat hozirda dori vositasining ixtisoslashtirilgan onkologiya markazlari bo'ylab tarqatilishini kengaytirishga e'tibor qaratgan.

Fennec Pharmaceuticals (FENC): Uzoq muddatli qarzning kapitalga nisbati 04.07.2022dan 28.10.2026gacha
Fennec Pharmaceuticals asosiy tovari

Ushbu koeffitsiyent kompaniyaning o'z kapitaliga nisbatan uzoq muddatli qarzlarga bog'liqligini o'lchaydi, bu esa bozorlar beqarorligi davrida moliyaviy barqarorlik va defolt xavfini belgilaydi. Uzoq muddatli qarzning kapitalga nisbati tahlili Fennec Pharmaceuticals (FENC) kompaniyasini va uning shifoxonalarga uzluksiz yetkazib berishni ta'minlash uchun muhim bo'lgan pediatrik onkologiya dori vositalarining murakkab logistikasini haddan tashqari kredit bosimisiz moliyalashtirish qobiliyatini baholash imkonini beradi.

Raqobatchilar tahlili

Uzoq muddatli qarzdorlikning o'z kapitaliga nisbati Incyte Corp|HUTCHMED Ltd - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati NUVB (Nuvation Corp)|DAWN - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi monopartx.com MNPR|INBX (Inhibrx Biosciences, Inc.) - Uzoq muddatli qarzning kapitalga nisbati|IMAB: Uzoq muddatli majburiyatlarning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati herontx.com HRTX|Nuvectis Pharma, Inc (NVCT) - Uzoq muddatli qarzning kapitalga koeffitsiyenti|CHRS (Coherus BioSciences Inc.) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzning kapitalga nisbati CRBP|Uzoq muddatli qarzning o'z kapitaliga nisbati Cardiff Oncology, Inc. (CRDF)|Uzoq muddatli qarzning o'z kapitaliga nisbati BeyondSpring, Inc. BYSI|Uzoq muddatli qarzning o'z kapitaliga nisbati BioAtla|Lixte Biotechnology, Inc. - Uzoq muddatli qarzning kapitalga koeffitsiyenti|CTXR (Citius Pharma) - Uzoq muddatli qarzning o'z kapitaliga nisbati|CLRB: Uzoq muddatli majburiyatlarning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati BioLineRx|Can-Fite BioPharma Ltd (CANF) - Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|Uzoq muddatli qarzning kapitalga nisbati APRE|Uzoq muddatli qarzning o'z kapitaliga nisbati KZIA|Silexion Therapeutics Corp - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati NCNA (nucana.com)|Uzoq muddatli qarzning o'z kapitaliga nisbati Chimerix CMRX|Cyclacel Pharmaceuticals, Inc. - Uzoq muddatli qarzning o'z kapitaliga nisbati|GTHX (G1 Pharma) - Uzoq muddatli qarzning o'z kapitaliga nisbati|KRON - Uzoq muddatli majburiyatlarning kapitalga nisbati|Uzoq muddatli qarzning kapitalga nisbati KTRA (Kintara Therapeutics)|Uzoq muddatli qarzdorlikning o'z kapitaliga nisbati oncternal.com|Uzoq muddatli qarzning o'z kapitaliga nisbati PRTG (Portage Biotech)